Dr. Sullenger is the Director of the Translational Research Institute (DTRI) and the Joseph and Dorothy Beard Professor of Surgery and the Vice Chair of Research in the Department of Surgery at Duke University Medical Center (Durham, NC). Dr. Sullenger also serves as the Scientific Director of the NHLBI supported Translational Research Center for Thrombotic and Hemostatic Disorders (TRC-THD) that he cofounded at Duke. He has authored over 120 papers published in basic science and translational research journals.

Dr. Sullenger’s research program focuses upon the discovery and development of therapeutic RNAs. His group has been a leader in the development of nucleic acid aptamers for inhibiting the activities of therapeutically important proteins including coagulation factors and platelet proteins. He is on the Board of Directors of the American Society of Gene and Cell Therapy and the Oligonucleotide Therapeutics Society and is Editor-in-Chief for the Society’s journal Nucleic Acid Therapeutics. Dr. Sullenger founded Regado Biosciences Inc, a company focused upon the development and commercialization of the aptamer-antidote technology his laboratory invented. The lead compound, an aptamer targeting factor IXa and its matched antidote, is in phase 3 clinical studies.

Dr. Sullenger earned his Bachelor of Science Degree from Indiana University (Bloomington, IN) and his Ph.D. from Cornell University Graduate School of Medical Sciences (New York, NY) working at the Memorial Sloan-Kettering Cancer Center. He performed postdoctoral studies at the University of Colorado (Boulder, CO) in the Department of Biochemistry in Dr. Thomas Cech’s laboratory.